BridgeMD
Improvement of Live Babies Rates After ICSI, Using cpFT
EU CTIS ID: 2024-514350-78-00
What this study is testing
Demonstration of the improvement in the rate of live births after ICSI by supplementing the pre-ICSI incubation medium of oocytes and that of preimplantation embryos with cpFT (1µM) during the 1st embryo transfer in women under 37 years of age.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- - Couples requiring Medically Assisted Reproduction (AMP).
- - Couples eligible for ICSI
- - Women 18 to 36 years old inclusive.
- - Men 18 to 58 years old inclusive
- - Use of CSCM-C culture medium from Biocare/Irvine, exclusively.
- - People affiliated to a Social Security system
You likely can't join if
- - Lack of consent from one or both couple members
- - Couples requiring IVF or Intra Uterine Insemination treatment.
- - Early menopause
- - People who cannot follow protocol survey in France.
- - Women with a contra-indication to ART treatment or an associated pathology such as: hypertension, risk of eclampsia, family genetic problems, diabetes, uterine septations, synechiae adhesions, adenomyosis or any other contra-indication judged as such by the investigator.
- - ART with gamete or embryo donation.
See the full eligibility criteria
- - Couples requiring Medically Assisted Reproduction (AMP).
- - Couples eligible for ICSI
- - Women 18 to 36 years old inclusive.
- - Men 18 to 58 years old inclusive
- - Use of CSCM-C culture medium from Biocare/Irvine, exclusively.
- - People affiliated to a Social Security system
- - Lack of consent from one or both couple members
- - Couples requiring IVF or Intra Uterine Insemination treatment.
- - Early menopause
- - People who cannot follow protocol survey in France.
- - Women with a contra-indication to ART treatment or an associated pathology such as: hypertension, risk of eclampsia, family genetic problems, diabetes, uterine septations, synechiae adhesions, adenomyosis or any other contra-indication judged as such by the investigator.
- - ART with gamete or embryo donation.
- - Participant under guardianship or curatorship
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.